Suchergebnisse - "Beltman, Jeri"

PubPharm (8)

1

Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib

enthalten in: Clinical pharmacokinetics | 2022

von Liao, M. | Beltman, J. | Giordano, H. | +4

2

Population pharmacokinetics of rucaparib in patients with advanced ovarian cancer or other solid tumors

enthalten in: Cancer chemotherapy and pharmacology | 2022

von Green, M. | Ma, S. | Goble, S. | +6

3

Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment

enthalten in: Cancer chemotherapy and pharmacology | 2021

von Grechko, N. | Skarbova, V. | Tomaszewska-Kiecana, M. | +10

4

Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2

enthalten in: Gynecologic oncology | 2021

von Konecny, G. | Oza, A. | Tinker, A. | +23

5

Evaluation of in vitro absorption, distribution, metabolism, and excretion and assessment of drug-drug interaction of rucaparib, an orally potent poly(ADP-ribose) polymerase inhibitor

enthalten in: Xenobiotica; the fate of foreign compounds in biological systems | 2020

von Liao, M. | Jaw-Tsai, S. | Beltman, J. | +3

6

Evaluation of absorption, distribution, metabolism, and excretion of [14C]-rucaparib, a poly(ADP-ribose) polymerase inhibitor, in patients with advanced solid tumors

enthalten in: Investigational new drugs | 2020

von Liao, M. | Watkins, S. | Nash, E. | +10

7

Evaluation ofin vitroabsorption, distribution, metabolism, and excretion and assessment of drug-drug interaction of rucaparib, an orally potent poly(ADP-ribose) polymerase inhibitor

enthalten in: Xenobiotica | 2020

von Liao, M. | Jaw-Tsai, S. | Beltman, J. | +3

8

Evaluation of Drug-Drug Interactions of Rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P-gp Substrates in Patients With an Advanced Solid Tumor

enthalten in: Clinical and translational science | 2019

von Xiao, J. | Nowak, D. | Ramlau, R. | +8

1
[1]